William D Travis

List of Publications by Citations

284 papers	**47,037** citations	**101** h-index	**215** g-index
313 ext. papers	**57,777** ext. citations	**6.7** avg, IF	**7.19** L-index

#	Paper	IF	Citations
284	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 244-85	8.9	3178
283	Somatic mutations affect key pathways in lung adenocarcinoma. *Nature*, **2008**, 455, 1069-75	50.4	2280
282	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
281	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 39-51	8.9	1888
280	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
279	Comprehensive genomic profiles of small cell lung cancer. *Nature*, **2015**, 524, 47-53	50.4	1061
278	Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology*, **2017**, 284, 228-243	20.5	951
277	Characterizing the cancer genome in lung adenocarcinoma. *Nature*, **2007**, 450, 893-8	50.4	900
276	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nature Medicine*, **2008**, 14, 822-7	50.5	835
275	Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. *American Journal of Surgical Pathology*, **1991**, 15, 529-53	6.7	719
274	Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. *Radiology*, **2013**, 266, 304-17	20.5	696
273	Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Modern Pathology*, **2011**, 24, 653-64	9.8	693
272	Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. *American Journal of Surgical Pathology*, **1998**, 22, 934-44	6.7	668
271	Lung cancer. *Cancer*, **1995**, 75, 191-202	6.4	575
270	The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology*, **2007**, 2, 593-602	8.9	563
269	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respiratory Medicine,the*, **2018**, 6, 138-153	35.1	452
268	The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2015**, 10, 990-1003	8.9	451

267	Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 904-10	10.2	450
266	Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. *American Journal of Surgical Pathology*, **2000**, 24, 19-33	6.7	440
265	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Modern Pathology*, **2018**, 31, 1770-1786	9.8	428
264	Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1338-47	10.2	425
263	EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. *Genes Chromosomes and Cancer*, **2010**, 49, 1114-24	5	368
262	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. *Journal of Clinical Oncology*, **2013**, 31, 992-1001	2.2	365
261	Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 647-67	5	346
260	Pathology of lung cancer. *Clinics in Chest Medicine*, **2011**, 32, 669-92	5.3	346
259	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proceedings of the American Thoracic Society*, **2011**, 8, 381-5		346
258	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 1204-1223	8.9	333
257	Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. *American Journal of Surgical Pathology*, **2002**, 26, 1184-97	6.7	331
256	A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. *Science Translational Medicine*, **2015**, 7, 302ra136	17.5	329
255	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 89-108	5	315
254	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. *American Journal of Surgical Pathology*, **2008**, 32, 810-27	6.7	315
253	Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. *Human Pathology*, **2003**, 34, 743-8	3.7	309
252	Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. *Cancer*, **1994**, 73, 2936-45	6.4	309
251	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. *Journal of Thoracic Oncology*, **2013**, 8, 52-61	8.9	306
250	Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. *Archives of Pathology and Laboratory Medicine*, **2010**, 134, 235-43	5	304

249 — Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. *Clinical Cancer Research*, **2012**, 18, 1167-76 — 12.9 — 297

248 — p40 (Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. *Modern Pathology*, **2012**, 25, 405-15 — 9.8 — 295

247 — Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. *Cancer Research*, **2004**, 64, 2307-16 — 10.1 — 291

246 — Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 668-84 — 5 — 287

245 — Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. *Modern Pathology*, **2011**, 24, 1348-59 — 9.8 — 268

244 — A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. *American Journal of Surgical Pathology*, **2000**, 24, 906-16 — 6.7 — 268

243 — Integrative Molecular Characterization of Malignant Pleural Mesothelioma. *Cancer Discovery*, **2018**, 8, 1548-1565 — 24.4 — 258

242 — Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 412-441 — 7.3 — 248

241 — Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. *Journal of Thoracic Oncology*, **2015**, 10, 806-814 — 8.9 — 246

240 — A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. *American Journal of Surgical Pathology*, **2010**, 34, 1155-62 — 6.7 — 246

239 — Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. *Clinical Cancer Research*, **2016**, 22, 3618-29 — 12.9 — 242

238 — A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. *American Journal of Surgical Pathology*, **1990**, 14, 1112-25 — 6.7 — 240

237 — Reproducibility of neuroendocrine lung tumor classification. *Human Pathology*, **1998**, 29, 272-9 — 3.7 — 228

236 — Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 639-44 — 10.2 — 224

235 — Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. *Journal of Clinical Oncology*, **2005**, 23, 3279-87 — 2.2 — 223

234 — The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 300-11 — 8.9 — 218

233 — The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2008**, 3, 1213-23 — 8.9 — 213

232 — Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. *Lancet Oncology, The*, **2014**, 15, e42-50 — 21.7 — 210

231	Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology*, **2008**, 3, 1384-90	8.9	197
230	Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. *Journal of Thoracic Oncology*, **2011**, 6, 451-8	8.9	196
229	The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. *Journal of Thoracic Oncology*, **2016**, 11, 142-54	8.9	195
228	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1109-1121	8.9	193
227	Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. *American Journal of Surgical Pathology*, **2009**, 33, 1752-64	6.7	179
226	United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. *Cancer*, **1996**, 77, 2464-70	6.4	179
225	ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. *Journal of Thoracic Oncology*, **2014**, 9, 596-611	8.9	177
224	Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *Ca-A Cancer Journal for Clinicians*, **2017**, 67, 138-155	220.7	175
223	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nature Communications*, **2014**, 5, 3518	17.4	173
222	Lung cancer screening. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 240-65	7.3	171
221	Genetic changes in the spectrum of neuroendocrine lung tumors. *Cancer*, **1999**, 85, 600-7	6.4	170
220	Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Modern Pathology*, **2012**, 25 Suppl 1, S18-30	9.8	169
219	Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. *Journal of the National Cancer Institute*, **2013**, 105, 1212-20	9.7	162
218	Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. *American Journal of Surgical Pathology*, **2014**, 38, 448-60	6.7	159
217	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. *Modern Pathology*, **2012**, 25, 1574-83	9.8	155
216	Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. *Lung Cancer*, **2009**, 64, 148-54	5.9	155
215	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. *Nature Communications*, **2018**, 9, 1048	17.4	152
214	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 651-665	8.9	148

213	Radiologic implications of the 2011 classification of adenocarcinoma of the lung. *Radiology*, **2013**, 266, 62-71	20.5	147
212	Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. *Journal of Thoracic Oncology*, **2010**, 5, 411-4	8.9	144
211	Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor 2 (IL-12R2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. *Journal of Clinical Oncology*, **2013**, 31, 490-8	2.2	141
210	Thymic carcinoma outcomes and prognosis: results of an international analysis. *Journal of Thoracic and Cardiovascular Surgery*, **2015**, 149, 95-100, 101.e1-2	1.5	140
209	US lung cancer trends by histologic type. *Cancer*, **2014**, 120, 2883-92	6.4	139
208	The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. *Human Pathology*, **2003**, 34, 136-42	3.7	135
207	Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. *Journal of Thoracic Oncology*, **2014**, 9, 273-84	8.9	130
206	Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. *Seminars in Respiratory and Critical Care Medicine*, **2011**, 32, 22-31	3.9	128
205	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 1433-46	8.9	127
204	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. *Journal of Clinical Oncology*, **2015**, 33, 2877-84	2.2	124
203	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *Journal of Thoracic Oncology*, **2016**, 11, 639-650	8.9	122
202	Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. *Clinical Cancer Research*, **2010**, 16, 240-8	12.9	122
201	Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 1210-2	10.2	119
200	The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. *American Journal of Clinical Pathology*, **1994**, 102, 406-14	1.9	118
199	Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 685-705	5	117
198	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *Journal of Thoracic Oncology*, **2016**, 11, 666-680	8.9	116
197	Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. *Clinical Cancer Research*, **2009**, 15, 5184-90	12.9	115
196	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 377-407	8.9	114

195	A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Modern Pathology*, **2012**, 25, 1117-27	9.8	113
194	Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clinical Cancer Research*, **2012**, 18, 1138-45	12.9	110
193	Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. *Archives of Pathology and Laboratory Medicine*, **2000**, 124, 267-75	5	108
192	A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. *Modern Pathology*, **2012**, 25, 260-71	9.8	107
191	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1249-1254	10.2	105
190	Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *American Journal of Surgical Pathology*, **2014**, 38, 1118-27	6.7	104
189	Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. *Journal of Thoracic Oncology*, **2011**, 6, 1849-56	8.9	103
188	Pathologic characteristics of drug-induced lung disease. *Clinics in Chest Medicine*, **2004**, 25, 37-45	5.3	103
187	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. *Journal of Thoracic Oncology*, **2006**, 1, S13-S19	8.9	100
186	An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2016**, 22, 4880-4889	12.9	99
185	Sarcomatoid neoplasms of the lung and pleura. *Archives of Pathology and Laboratory Medicine*, **2010**, 134, 1645-58	5	98
184	Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. *Clinical Cancer Research*, **2014**, 20, 1020-8	12.9	96
183	A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. *Chest*, **2013**, 143, 825-839	5.3	96
182	Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. *Journal of Thoracic Oncology*, **2011**, 6, 896-904	8.9	93
181	Predictors of outcomes after surgical treatment of synchronous primary lung cancers. *Journal of Thoracic Oncology*, **2010**, 5, 197-205	8.9	91
180	Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. *American Journal of Surgical Pathology*, **2005**, 29, 948-54	6.7	91
179	The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. *OncoImmunology*, **2015**, 4, e1009285	7.2	88
178	Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. *American Journal of Surgical Pathology*, **2015**, 39, 132-9	6.7	88

177	Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 1977-1986	5.6	86
176	The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. *Modern Pathology*, **2014**, 27, 690-700	9.8	85
175	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. *Clinical Lung Cancer*, **2016**, 17, e121-e129	4.9	83
174	Clear cell "sugar" tumor of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. *American Journal of Surgical Pathology*, **1997**, 21, 1242-7	6.7	83
173	Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. *Chest*, **2010**, 137, 46-52	5.3	82
172	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. *Journal of Thoracic Oncology*, **2020**, 15, 231-247	8.9	82
171	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. *Journal of Thoracic Oncology*, **2017**, 12, 223-234	8.9	81
170	Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. *Journal of Thoracic Oncology*, **2014**, 9, 456-63	8.9	81
169	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. *Modern Pathology*, **2013**, 26, 511-22	9.8	81
168	Lung tumours with neuroendocrine differentiation. *European Journal of Cancer*, **2009**, 45 Suppl 1, 251-66	7.5	81
167	Lung tumors with a rhabdoid phenotype. *American Journal of Clinical Pathology*, **1996**, 105, 182-8	1.9	81
166	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. *Journal of Thoracic Oncology*, **2020**, 15, 1409-1424	8.9	80
165	Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. *Thoracic Surgery Clinics*, **2014**, 24, 257-66	3.1	80
164	Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. *Journal of Thoracic Oncology*, **2013**, 8, 1084-90	8.9	79
163	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ⏞3 cm: accuracy and interobserver agreement. *Histopathology*, **2015**, 66, 922-38	7.3	77
162	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *Journal of Thoracic Oncology*, **2020**, 15, 709-740	8.9	77
161	Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. *Journal of Thoracic and Cardiovascular Surgery*, **2015**, 149, 103-9.e2	1.5	76
160	Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 23-34; quiz 34	7.3	75

159	Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors. *Journal of Thoracic Oncology*, **2014**, 9, 1573-8	8.9	75
158	FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Annals of Surgical Oncology*, **2012**, 19, 3598-605	3.1	75
157	Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. *Annals of Thoracic Surgery*, **2011**, 92, 1180-6; discussion 1186-7	2.7	75
156	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. *Journal of Thoracic Oncology*, **2019**, 14, 87-98	8.9	75
155	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. *Modern Pathology*, **2018**, 31, 581-597	9.8	75
154	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 681-692	8.9	74
153	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 1818-1831	8.9	73
152	The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. *Journal of Thoracic Oncology*, **2015**, 10, 553-64	8.9	71
151	Cystic Lung Diseases: Algorithmic Approach. *Chest*, **2016**, 150, 945-965	5.3	70
150	American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. *Radiographics*, **2015**, 35, 1849-71	5.4	69
149	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. *Journal of Thoracic Oncology*, **2017**, 12, 334-346	8.9	67
148	Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. *Journal of Thoracic Oncology*, **2014**, 9, 1126-39	8.9	67
147	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. *Journal of Thoracic Oncology*, **2020**, 15, 1823-1835	8.9	63
146	Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. *Histopathology*, **2020**, 77, 915-925	7.3	62
145	MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. *Genes Chromosomes and Cancer*, **2000**, 28, 58-65	5	61
144	Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1721-8	7.4	60
143	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. *Journal of Thoracic Oncology*, **2020**, 15, 29-49	8.9	58
142	Pathologic findings of lung tumors diagnosed on baseline CT screening. *American Journal of Surgical Pathology*, **2006**, 30, 606-13	6.7	57

No.	Reference	Factor	Cites
141	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. *Hepatology*, **1995**, 22, 1163-1170	11.2	54
140	Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. *European Journal of Cardio-thoracic Surgery*, **2015**, 48, 441-7; discussion 447	3	53
139	The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. *Seminars in Thoracic and Cardiovascular Surgery*, **2014**, 26, 210-22	1.7	53
138	Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. *Histopathology*, **2009**, 54, 3-11	7.3	53
137	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. *Journal of Thoracic Oncology*, **2020**, 15, 1599-1610	8.9	52
136	Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. *Annals of Thoracic Surgery*, **2013**, 96, 1156-1162	2.7	52
135	Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. *Modern Pathology*, **2018**, 31, 598-606	9.8	51
134	An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. *Cancer*, **1991**, 68, 2169-74	6.4	51
133	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. *European Journal of Cardio-thoracic Surgery*, **2016**, 49, e9-e15	3	50
132	Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. A study of 17 patients. *American Journal of Clinical Pathology*, **1989**, 91, 558-62	1.9	50
131	Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. *American Journal of Surgical Pathology*, **2015**, 39, 1170-80	6.7	49
130	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. *Modern Pathology*, **2020**, 33, 591-602	9.8	46
129	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. *Cancer Discovery*, **2021**, 11, 2748-2763	24.4	46
128	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. *Modern Pathology*, **2019**, 32, 1106-1122	9.8	43
127	Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 32-40	5	43
126	Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. *PLoS ONE*, **2010**, 5, e11712	3.7	43
125	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. *Journal of Thoracic Oncology*, **2020**, 15, 520-540	8.9	42
124	Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach. *Chest*, **2018**, 153, 1443-1465	5.3	42

#	Reference		
123	A combined small cell and spindle cell carcinoma of the lung. Report of a unique case with immunohistochemical and ultrastructural studies. *American Journal of Surgical Pathology*, **1992**, 16, 1108-15	6.7	42
122	Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. *Cancer*, **1990**, 66, 1513-6	6.4	42
121	Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases. *American Journal of Surgical Pathology*, **2018**, 42, 1010-1026	6.7	42
120	Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study. *Genes Chromosomes and Cancer*, **2014**, 53, 738-49	5	41
119	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. *Modern Pathology*, **2020**, 33, 303-311	9.8	41
118	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. *Journal of Thoracic Oncology*, **2019**, 14, 825-834	8.9	40
117	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. *Annals of Thoracic Surgery*, **2017**, 104, e217-e218	2.7	40
116	Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases. *Cancer*, **1985**, 56, 602-8	6.4	40
115	Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines. *Diagnostic Cytopathology*, **2016**, 44, 399-409	1.4	39
114	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. *Journal of Thoracic Oncology*, **2019**, 14, 482-493	8.9	39
113	Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China. *Histopathology*, **2021**, 78, 542-555	7.3	39
112	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. *Modern Pathology*, **2018**, 31, 111-121	9.8	38
111	Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. *Cancer*, **2013**, 119, 931-8	6.4	37
110	Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary Sjögren syndrome. *Arthritis and Rheumatism*, **1992**, 35, 1368-72		37
109	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. *Clinical Cancer Research*, **2019**, 25, 7113-7125	12.9	36
108	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. *Journal of Thoracic Oncology*, **2006**, 1, S13-S19	8.9	36
107	Lung cancer staging: a concise update. *European Respiratory Journal*, **2018**, 51,	13.6	34
106	Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. *Lung Cancer*, **2014**, 86, 237-40	5.9	33

105	Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. *Chest*, **2015**, 148, 711-721	5.3	33
104	Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor. *Journal of Thoracic Oncology*, **2015**, 10, 1301-1310	8.9	33
103	Classification of lung cancer. *Seminars in Roentgenology*, **2011**, 46, 178-86	0.8	32
102	Lung Cancer Pathology: Current Concepts. *Clinics in Chest Medicine*, **2020**, 41, 67-85	5.3	32
101	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. *American Journal of Surgical Pathology*, **2016**, 40, 1579-1590	6.7	32
100	Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. *European Journal of Cardio-thoracic Surgery*, **2016**, 50, 766-771	3	32
99	Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. *Journal of Thoracic Oncology*, **2014**, 9, 1354-62	8.9	31
98	Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. *Archives of Pathology and Laboratory Medicine*, **2000**, 124, 1642-8	5	31
97	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2020**, 15, 589-600	8.9	31
96	Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis. *Genes Chromosomes and Cancer*, **2015**, 54, 463-471	5	30
95	Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma 2 cm: a proposal to reclassify T1 lung adenocarcinoma. *Chest*, **2013**, 144, 1622-1631	5.3	30
94	Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. *Journal of Thoracic Oncology*, **2006**, 1, S13-9	8.9	30
93	A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. *Journal of Clinical Pathology*, **2015**, 68, 441-7	3.9	29
92	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. *Journal of Thoracic Oncology*, **2018**, 13, 801-809	8.9	29
91	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. *Journal of Thoracic Oncology*, **2019**, 14, 1583-1593	8.9	29
90	Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. *Annals of Surgical Oncology*, **2013**, 20 Suppl 3, S676-83	3.1	29
89	The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. *American Journal of Surgical Pathology*, **2011**, 35, 1823-9	6.7	29
88	Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. *Journal of Thoracic Oncology*, **2016**, 11, 537-44	8.9	28

87	Pathologic classification of adenocarcinoma of lung. *Journal of Surgical Oncology*, **2013**, 108, 320-6	2.8	28
86	High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. *Journal of Thoracic Oncology*, **2012**, 7, 1192-7	8.9	28
85	Pulmonary neuroendocrine tumors: What (little) do we know?. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 623-30	7.3	28
84	A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. *Journal of Urology*, **1991**, 145, 1040-2	2.5	28
83	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. *Journal of Thoracic Oncology*, **2020**, 15, 1037-1053	8.9	27
82	Smoking-related idiopathic interstitial pneumonia. *European Respiratory Journal*, **2014**, 44, 594-602	13.6	27
81	Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 138-145	4	27
80	Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2020**, 15, 792-802	8.9	26
79	Aspiration cytomorphology of fetal adenocarcinoma of the lung. *American Journal of Clinical Pathology*, **2010**, 134, 894-902	1.9	26
78	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. *Journal of Thoracic Oncology*, **2021**,	8.9	26
77	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (2 cm) Lung Adenocarcinoma: An International Cohort Analysis. *Journal of Thoracic Oncology*, **2019**, 14, 72-86	8.9	26
76	Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. *European Respiratory Journal*, **2013**, 42, 1332-44	13.6	25
75	Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids. *Cancer Research*, **2019**, 79, 4339-4347	10.1	23
74	Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. *Cancer Cytopathology*, **2012**, 120, 35-43	3.9	23
73	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. *Lung Cancer*, **2017**, 108, 205-211	5.9	22
72	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. *Journal of Thoracic Oncology*, **2018**, 13, 205-217	8.9	22
71	Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. *Molecular and Clinical Oncology*, **2013**, 1, 437-443	1.6	21
70	Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study. *Lung Cancer*, **2008**, 62, 202-14	5.9	21

69	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. *Journal of Thoracic Oncology*, **2019**, 14, 1948-1961	8.9	20
68	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. *Journal of Thoracic Oncology*, **2014**, 9, 141-3	8.9	20
67	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. *Oncotarget*, **2017**, 8, 77872-77882	3.3	20
66	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2020**, 15, 1844-1856	8.9	20
65	Usual interstitial pneumonia. *Seminars in Respiratory and Critical Care Medicine*, **2001**, 22, 357-86	3.9	18
64	Nuclear estrogen receptor-expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. *Oncotarget*, **2015**, 6, 27505-18	3.3	17
63	Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 1552-9	5	17
62	Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. *Science Translational Medicine*, **2021**, 13, eabj7790	17.5	17
61	Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report. *Chest*, **2021**, 160, e97-e156	5.3	17
60	Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance. *Oncotarget*, **2018**, 9, 35742-35751	3.3	16
59	Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 339-345	3	15
58	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. *Applied Immunohistochemistry and Molecular Morphology*, **2021**, 29, 5-12	1.9	15
57	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. *Radiology*, **2021**, 298, 550-566	20.5	15
56	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest*, **2021**, 159, 1107-1125	5.3	15
55	Testing for Neuroendocrine Immunohistochemical Markers Should Not Be Performed in Poorly Differentiated NSCCs in the Absence of Neuroendocrine Morphologic Features according to the 2015 WHO Classification. *Journal of Thoracic Oncology*, **2016**, 11, e26-7	8.9	15
54	Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2018**, 13, 1919-1929	8.9	15
53	Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. *Oncotarget*, **2016**, 7, 35241-56	3.3	14
52	Lung **2017**, 431-456		14

51	Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 645-661	5	13
50	What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. *Lung Cancer*, **2018**, 118, 83-89	5.9	13
49	Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection. *Journal of Cardiothoracic Surgery*, **2011**, 6, 27	1.6	13
48	Counting mitoses: SI(ze) matters!. *Modern Pathology*, **2021**, 34, 1651-1657	9.8	13
47	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. *Modern Pathology*, **2020**, 33, 2244-2255	9.8	12
46	Carcinoma in situ at the bronchial resection margin: a review. *Journal of Thoracic Oncology*, **2011**, 6, 1617-23	82.3	12
45	Megakaryoblastic transformation of chronic granulocytic leukemia. *Cancer*, **1987**, 60, 193-200	6.4	12
44	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. *Clinical Cancer Research* , **2021**, 27, 4066-4076	12.9	12
43	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 157, 743-753.e3	1.5	12
42	Recent advances in our understanding of lung cancer visceral pleural invasion and other forms of minimal invasion: implications for the next TNM classification. *European Journal of Cardio-thoracic Surgery*, **2013**, 43, 309-11	3	11
41	Endotracheal myoepithelioma. *Chest*, **2011**, 140, 242-244	5.3	10
40	Updated protocol for the examination of specimens from patients with carcinoma of the lung. *Archives of Pathology and Laboratory Medicine*, **2003**, 127, 1304-13	5	10
39	BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. *Journal of Thoracic Oncology*, **2018**, 13, 73-84	8.9	10
38	Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma. *Annals of Thoracic Surgery*, **2019**, 108, 392-398	2.7	9
37	Neuroendocrine Lung Tumors **2006**, 11, 235-242		9
36	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. *Journal of Thoracic Oncology*, **2021**,	8.9	9
35	The 2021 World Health Organization Classification of Tumors of the Pleura: Advances since the 2015 Classification.. *Journal of Thoracic Oncology*, **2022**,	8.9	8
34	Identification and Functional Characterization of V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. *JCO Precision Oncology*, **2017**, 1,	3.6	7

33	Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. *Cell Reports*, **2021**, 34, 108707	10.6	7
32	Executive Summary: Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report. *Chest*, **2021**, 160, 595-615	5.3	7
31	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach. *Journal of Clinical Oncology*, **2020**, 38, 1633-1640	2.2	6
30	Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 816-818	10.2	6
29	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. *Journal of Thoracic Oncology*, **2021**, 16, 1188-1199	8.9	6
28	Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. *Lung Cancer*, **2015**, 89, 329-36	5.9	5
27	Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma. *Annals of Surgical Oncology*, **2015**, 22, 3136-43	3.1	5
26	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. *Journal of Thoracic Oncology*, **2019**, 14, 1989-1994	8.9	5
25	The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer. *OncoImmunology*, **2014**, 3, e967142	7.2	5
24	Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results. *Journal of Molecular Diagnostics*, **2021**, 23, 310-322	5.1	5
23	Forty years of the international association for study of lung cancer pathology committee. *Journal of Thoracic Oncology*, **2014**, 9, 1740-9	8.9	4
22	Molecular Characterization of Peritoneal Mesotheliomas. *Journal of Thoracic Oncology*, **2021**,	8.9	4
21	Diagnostic criteria for idiopathic pulmonary fibrosis - Authors'reply. *Lancet Respiratory Medicine,the* , **2018**, 6, e7	35.1	3
20	Surgical lung biopsy in the diagnosis of idiopathic NSIP: do we always need it in the initial approach?. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 1071; author reply 1071-2	10.2	3
19	The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms. *Pathologica*, **2021**, 113, 377-387	1.9	3
18	Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment. *Annals of Thoracic Surgery*, **2021**, 111, 1028-1035	2.7	3
17	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. *Journal of Thoracic Oncology*, **2020**, 15, e121-e124	8.9	2
16	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. *Journal of Thoracic Oncology*, **2020**, 15, e118-e120	8.9	1

LIST OF PUBLICATIONS

15	Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 256-256	10.2	1
14	Large Cell Neuroendocrine Carcinoma **2006**, 298-306		1
13	E12-01: NCI Director's challenge gene profiling of lung adenocarcinomas: impact on histologic classification. *Journal of Thoracic Oncology*, **2007**, 2, S254-S256	8.9	1
12	Molecular differences across invasive lung adenocarcinoma morphological subgroups. *Translational Lung Cancer Research*, **2020**, 9, 1029-1040	4.4	1
11	Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. *Journal of Thoracic Oncology*, **2021**, 16, e9-e10	8.9	1
10	Type A thymoma presenting with bone metastasis. *Histopathology*, **2018**, 73, 701-703	7.3	1
9	Spread Through Air Spaces (STAS) in Non-Small Cell Lung Carcinoma: Evidence Supportive of an In Vivo Phenomenon. *American Journal of Surgical Pathology*, **2021**, 45, 1509-1515	6.7	0
8	Histologic Classification and Its Need for Treatment of Lung Cancer **2015**, 1-14		
7	Pathology: Malignant and Interstitial Lung Diseases **2016**, 225-250.e7		
6	Pathology of Adenocarcinoma **2014**, 144-157		
5	Interstitial lung disease. *Diagnostic Histopathology*, **2008**, 14, 499-508	0.7	
4	Lung Cancer Pathology Blueprint for Future Work. *Japanese Journal of Lung Cancer*, **2007**, 47, 903-903	0.1	
3	Pulmonary Pathology Society Lifetime Achievement Award, 2007: Raymond Yesner, MD, professor of pathology emeritus, Yale University School of Medicine. *Archives of Pathology and Laboratory Medicine*, **2007**, 131, 1634	5	
2	Lung Pathology **2009**, 71-87		
1	Endocrine Lung **2010**, 429-445		